<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04767035</url>
  </required_header>
  <id_info>
    <org_study_id>MELT-100-002</org_study_id>
    <nct_id>NCT04767035</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability Study of MELT-100, IV Midazolam, and IV Ketamine</brief_title>
  <official_title>A Pivotal Phase 1, Randomized, Single-Dose, 4-Period, Crossover Relative Bioavailability Study of MELT-100, IV Midazolam, and IV Ketamine Under Fasted Conditions in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melt Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Worldwide Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Melt Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Pivotal Phase 1, Randomized, Single-Dose, 4-Period, Crossover Relative Bioavailability&#xD;
      Study of MELT-100, IV Midazolam, and IV Ketamine under Fasted Conditions in Healthy&#xD;
      Volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Pivotal Phase 1, Randomized, Single-Dose, 4-Period, Crossover Relative Bioavailability&#xD;
      Study of 2 doses of 3.5mgMELT-100, IV Midazolam, and IV Ketamine 18mg under Fasted Conditions&#xD;
      in Healthy Volunteers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Actual">January 14, 2021</completion_date>
  <primary_completion_date type="Actual">January 14, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>4-period 4-arm crossover relative bioavailability</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>24 hours</time_frame>
    <description>Maximum Concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>24 hours</time_frame>
    <description>Area under the curve</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Procedural Sedation</condition>
  <arm_group>
    <arm_group_label>MELT-100 3/25</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MELT-100 3mg midazolam / 25 mg ketamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MELT-100 2 x 3/25</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MELT-100 2 doses of 3mg midazolam / 25mg ketamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ketamine IV 18mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam IV 3.5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam / ketamine sublingual tablet</intervention_name>
    <description>sublingual tablet</description>
    <arm_group_label>MELT-100 2 x 3/25</arm_group_label>
    <arm_group_label>MELT-100 3/25</arm_group_label>
    <arm_group_label>Midazolam IV 3.5mg</arm_group_label>
    <arm_group_label>ketamine IV 18mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Able to understand and voluntarily consent to participation in this study and&#xD;
             provides written informed consent before the start of any study-specific procedures.&#xD;
&#xD;
             2. Healthy adult male or female at least 55 years of age. 3. Negative test for&#xD;
             SARS-CoV2 (COVID-19) 4. Normally active and otherwise judged to be in good health on&#xD;
             the basis of medical history and physical examination.&#xD;
&#xD;
             5. Has vital signs (measured sitting after a minimum 3 minutes of rest) at Screening&#xD;
             within the following ranges: heart rate: 40 to 100 bpm; systolic blood pressure (BP):&#xD;
             90 to145 mmHg; diastolic BP: 50 to 95 mmHg. Out-of-range vital signs may be repeated&#xD;
             once.&#xD;
&#xD;
             6. Has a body temperature â‰¤37.7 degrees C 7. Body weight at least 55 kg 8. Body mass&#xD;
             index (BMI) 18.0 to 32.0 kg/m2 (inclusive) 9. Female subjects are eligible only if the&#xD;
             following applies: Surgically sterile (bilateral tubal ligation, hysterectomy, or&#xD;
             bilateral oophorectomy), or postmenopausal (confirmed with serum FSH at Screening) 10.&#xD;
             Male subjects must either be surgically sterile (vasectomy at least 3 months prior to&#xD;
             first dose) or agree to use an acceptable method of birth control (see Section 4.4)&#xD;
             from Screening through EOS.&#xD;
&#xD;
             11. Is willing and able to remain in the study unit for the entire duration of each&#xD;
             confinement period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. History or presence of clinically significant cardiovascular, pulmonary, hepatic,&#xD;
             renal, hematologic, gastrointestinal, endocrine, immunologic, ophthalmologic,&#xD;
             dermatologic, neurologic, oncologic, or psychiatric disease or any other condition&#xD;
             that, in the opinion of the Investigator, would jeopardize the safety of the subject&#xD;
             or the validity of the study results.&#xD;
&#xD;
             2. Has a history of glaucoma, asthma, chronic obstructive pulmonary disease, or&#xD;
             thyroid disease.&#xD;
&#xD;
             3. History and/or family history of congenital long QT syndrome, unexplained syncope,&#xD;
             or other additional risks for Torsade de Pointes, or sudden premature death.&#xD;
&#xD;
             4. Clinically significant illnesses within 4 weeks of the administration of study&#xD;
             medication (including flu, flu-like symptoms, diarrhea, vomiting, fever, sore throat)&#xD;
             or acute illness at the time of either the pre-study medical evaluation or dosing.&#xD;
&#xD;
             5. Has been in contact with someone within the last month who has tested positive for&#xD;
             SARS-CoV-2.&#xD;
&#xD;
             6. History of COVID-19. 7. Clinically significant surgery within 4 weeks prior to the&#xD;
             administration of the study medication.&#xD;
&#xD;
             8. Has participated in another clinical trial (randomized subjects only) within 30&#xD;
             days before the first dose of study medication.&#xD;
&#xD;
             9. An active malignancy of any type or has been diagnosed with cancer within 5 years&#xD;
             prior to Screening (excluding squamous or basal cell carcinoma of the skin).&#xD;
&#xD;
             10. History or presence of allergic or adverse response to midazolam, ketamine, 11.&#xD;
             Use of any over-the-counter (OTC) medication (including nutritional or dietary&#xD;
             supplements, herbal preparations, or vitamins) within 14 days before the first dose of&#xD;
             study medication until the EOS without evaluation and approval by the Investigator.&#xD;
&#xD;
             12. Use of any prescription medication, except statin drugs or hormonal replacement&#xD;
             therapy, from 14 days before the first dose of study medication until the EOS without&#xD;
             evaluation and approval by the Investigator.&#xD;
&#xD;
             13. Have had a depot injection or an implant of any drugs 3 months prior to&#xD;
             administration of study medication.&#xD;
&#xD;
             14. Has been treated with any known drugs that are moderate or strong&#xD;
             inhibitors/inducers of cytochrome P450 (CYP) enzymes (e.g., barbiturates,&#xD;
             phenothiazines, cimetidine, carbamazepine) within 30 days before the first dose of&#xD;
             study medication, and that, in the Investigators judgment, may impact subject safety&#xD;
             or the validity of the study results.&#xD;
&#xD;
        Specifically, the use of any drugs known to inhibit CYP2C9 and CYP3A4 enzymes (for example,&#xD;
        amiodarone, fluconazole, ketoconazole, itraconazole, clarithromycin, ritonavir,&#xD;
        erythromycin) or any drugs that are highly protein-bound (for example, warfarin,&#xD;
        cyclosporine, amphotericin B) within 30 days prior to the first dose of study medication,&#xD;
        and that in the Investigator's judgment may impact subject safety or the validity of the&#xD;
        study results.&#xD;
&#xD;
        15. Blood or plasma donation within 30 days before the first dose of study medication until&#xD;
        the EOS. It is recommended that blood/plasma donations not be made for at least 30 days&#xD;
        after the EOS.&#xD;
&#xD;
        16. Has any prior history of substance abuse or treatment (including alcohol).&#xD;
&#xD;
          1. History of significant alcohol abuse within 6 months of Screening or any indication of&#xD;
             the regular use of more than 2 units of alcohol per day&#xD;
&#xD;
             (1 unit = 50 mL of wine or 360 mL of beer or 45 mL of alcohol 40%).&#xD;
&#xD;
          2. History of use of marijuana within 3 months of Screening or drugs such as cocaine,&#xD;
             phencyclidine (PCP), within 1 year of Screening.&#xD;
&#xD;
             17. Smoking or use of tobacco- or nicotine-containing products within 60 days before&#xD;
             the first dose of study medication until the EOS Note: Nonsmokers are preferred for&#xD;
             this study. 18. Any food allergy, intolerance, restriction, or special diet that, in&#xD;
             the opinion of the Investigator, contraindicates the subjects participation in this&#xD;
             study.&#xD;
&#xD;
             19. Has been on a significantly abnormal diet during the 4 weeks preceding the first&#xD;
             dose of study medication.&#xD;
&#xD;
             20. Consumption of beverages or foods that contain alcohol, poppy seeds, broccoli,&#xD;
             Brussels sprouts, pomegranate, star fruit, char-grilled meat, or caffeine/xanthine&#xD;
             from 48 hours before the first dose of study medication until the EOS.&#xD;
&#xD;
             Subject must not consume grapefruit, orange, or apple juice from 7 days before the&#xD;
             first dose of study medication until the EOS.&#xD;
&#xD;
             Subjects will be instructed not to consume any of the above products; however,&#xD;
             allowance for an isolated single incidental consumption may be evaluated and approved&#xD;
             by the study Investigator based on the potential for interaction with the study drug.&#xD;
&#xD;
             21. Engagement in strenuous exercise from 48 hours before the first dose of study&#xD;
             medication until the EOS.&#xD;
&#xD;
             22. A clinically significant abnormal finding on the physical examination, medical&#xD;
             history, or clinical laboratory results at Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Worldwide Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

